Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 1/20 | 0.43 |
| ▸ | RXRB | P28702 | 1/20 | 0.43 |
| ▸ | MRGPRX4 | Q96LA9 | 2/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.39 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.39 |
| ▸ | GGPS1 | O95749 | 1/20 | 0.39 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.38 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.38 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.38 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4202049 | 0.94 | RXRA (0.41) | RXRARXRBMRGPRX4THRBHDAC1 | |
| SCHEMBL4198439 | 0.94 | RXRA (0.46) | RXRARXRBMRGPRX4THRBHDAC1 | |
| SCHEMBL4202631 | 0.93 | THRB (0.46) | RXRARXRBMRGPRX4THRBHDAC1 | |
| SCHEMBL4192596 | 0.91 | RXRA (0.47) | RXRARXRBMRGPRX4THRBHDAC1 | |
| SCHEMBL4194734 | 0.90 | RXRA (0.40) | RXRARXRBMRGPRX4THRBPTGER4 | |
| SCHEMBL4188682 | 0.89 | MAPT (0.44) | THRBHDAC1HDAC2FFAR1 | |
| SCHEMBL4197888 | 0.88 | L3MBTL1 (0.44) | RXRARXRBTHRBPTGER4 | |
| SCHEMBL4194694 | 0.88 | THRB (0.46) | RXRARXRBTHRBFFAR1 | |
| SCHEMBL11957662 | 0.86 | THRB (0.51) | THRB | |
| SCHEMBL4196014 | 0.85 | RXRA (0.42) | RXRARXRBMRGPRX4THRBPTGER4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1627867-B1 | (METH)ACRYLIC ESTER COMPOUND AND USE THEREOF | MITSUI CHEMICALS INC (JP) | 2016-01-20 | — | — | EP | disclosed |
| US-7534909-B2 | (Meth) acrylic ester compound and use thereof | MITSUI CHEMICALS, INC. (JP) | 2009-05-19 | — | — | US | disclosed |
| US-20070078198-A1 | (Meth) acrylic ester compound and use thereof | MITSUI CHEMICALS, INC. (JP) | 2007-04-05 | — | — | US | disclosed |
| EP-1627867-A1 | (METH)ACRYLIC ESTER COMPOUND AND USE THEREOF | Mitsui Chemicals, Inc. (JP) | 2006-02-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070078198-A1 | (Meth) acrylic ester compound and use thereof | METTL14, PAM, TAS2R41 | RXRA 360/4885RXRB 538/4885MRGPRX4 589/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.